Grace Therapeutics annual shares outstanding
2022
2023
2024
Grace Therapeutics Shares Outstanding History (GRCE)
Grace Therapeutics reported 9.4M shares outstanding at the end of fiscal 2024.
View full Grace Therapeutics company overviewGrace Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-03-31 | 9.4M | 2.0M | +26.41% |
| 2023 | 2023-03-31 | 7.4M | −36.9M | −83.21% |
| 2022 | 2022-03-31 | 44.3M | — | — |
Grace Therapeutics quarterly shares outstanding
Q4.22
Q4.23
Q1.24
Q4.24
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
Q1.27
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-06-30 | 16.3M | 2.4M | +17.68% |
| Q4 2026 | 2026-03-31 | 16.0M | 2.3M | +16.81% |
| Q3 2026 | 2025-12-31 | 15.5M | 5.3M | +52.61% |
| Q2 2026 | 2025-09-30 | 14.1M | 4.7M | +50.31% |
| Q1 2026 | 2025-06-30 | 13.8M | 6.4M | +85.98% |
| Q4 2025 | 2025-03-31 | 13.7M | 6.3M | +84.49% |
| Q3 2025 | 2024-12-31 | 10.1M | −34.1M | −77.10% |
| Q4 2024 | 2024-03-31 | 9.4M | — | — |
| Q1 2024 | 2023-06-30 | 7.4M | — | — |
| Q4 2023 | 2023-03-31 | 7.4M | — | — |
| Q4 2022 | 2022-03-31 | 44.3M | — | — |
Grace Therapeutics shares outstanding trends
Across the available reported history, Grace Therapeutics's shares outstanding moved from 7.4M to 9.4M, a change of 2.0M. The latest reported quarter, Q1 2027, shows 16.3M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Grace Therapeutics filings at SEC.gov ↗